Neuberger Berman Group LLC increased its holdings in Chemed Corporation (NYSE:CHE - Free Report) by 3.9% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 521,212 shares of the company's stock after buying an additional 19,650 shares during the period. Neuberger Berman Group LLC owned about 3.56% of Chemed worth $320,712,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently bought and sold shares of the company. Cerity Partners LLC increased its holdings in Chemed by 13.0% in the 4th quarter. Cerity Partners LLC now owns 959 shares of the company's stock valued at $522,000 after purchasing an additional 110 shares during the last quarter. Advisory Services Network LLC lifted its position in Chemed by 13.1% during the 4th quarter. Advisory Services Network LLC now owns 482 shares of the company's stock worth $255,000 after acquiring an additional 56 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Chemed in the fourth quarter valued at approximately $42,023,000. Bessemer Group Inc. grew its holdings in Chemed by 16.2% during the fourth quarter. Bessemer Group Inc. now owns 832 shares of the company's stock worth $440,000 after acquiring an additional 116 shares during the period. Finally, Treasurer of the State of North Carolina lifted its position in shares of Chemed by 0.6% during the 4th quarter. Treasurer of the State of North Carolina now owns 6,526 shares of the company's stock valued at $3,457,000 after acquiring an additional 40 shares during the period. 95.85% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Chemed
In other news, Director George J. Walsh III acquired 200 shares of the stock in a transaction on Monday, August 4th. The shares were purchased at an average price of $417.10 per share, for a total transaction of $83,420.00. Following the transaction, the director directly owned 3,523 shares of the company's stock, valued at approximately $1,469,443.30. This represents a 6.02% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Nicholas Michael Westfall sold 10,012 shares of the stock in a transaction on Monday, August 4th. The stock was sold at an average price of $421.91, for a total value of $4,224,162.92. The disclosure for this sale can be found here. 3.29% of the stock is currently owned by corporate insiders.
Chemed Price Performance
Shares of CHE traded up $1.13 on Friday, hitting $445.00. The company's stock had a trading volume of 177,141 shares, compared to its average volume of 192,563. The company has a 50 day moving average price of $482.43 and a 200 day moving average price of $544.53. The company has a market capitalization of $6.48 billion, a PE ratio of 22.88, a PEG ratio of 2.45 and a beta of 0.46. Chemed Corporation has a fifty-two week low of $408.42 and a fifty-two week high of $623.60.
Chemed (NYSE:CHE - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $4.27 earnings per share for the quarter, missing the consensus estimate of $6.02 by ($1.75). The company had revenue of $618.80 million during the quarter, compared to analyst estimates of $650.60 million. Chemed had a net margin of 11.56% and a return on equity of 25.83%. The firm's quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the company earned $5.47 EPS. On average, equities analysts forecast that Chemed Corporation will post 21.43 EPS for the current year.
Chemed Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, August 29th. Stockholders of record on Monday, August 11th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, August 11th. This is a positive change from Chemed's previous quarterly dividend of $0.50. Chemed's payout ratio is currently 12.34%.
Wall Street Analysts Forecast Growth
CHE has been the subject of a number of recent analyst reports. Royal Bank Of Canada lowered their price objective on Chemed from $640.00 to $589.00 and set an "outperform" rating for the company in a research report on Thursday, July 31st. Oppenheimer reduced their target price on Chemed from $650.00 to $580.00 and set an "outperform" rating on the stock in a report on Thursday, July 31st. Jefferies Financial Group assumed coverage on Chemed in a research report on Friday, July 25th. They set a "hold" rating and a $500.00 price target on the stock. Wall Street Zen lowered shares of Chemed from a "buy" rating to a "hold" rating in a research report on Saturday, July 5th. Finally, Bank of America dropped their price objective on Chemed from $708.00 to $650.00 and set a "buy" rating on the stock in a research note on Monday, June 30th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $579.75.
Get Our Latest Report on CHE
About Chemed
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Further Reading

Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.